OncoSec’s CEO publishes article in Today’s Medical Developments

OncoSec Medical (OTC:ONCS) reported Tuesday its president and chief executive Punit Dhillon has written an article for Today’s
Medical Developments.

The biomedical company, founded in 2011, develops advance-stage ElectroOncology anti-cancer therapies to treat people with solid tumours.

The article entitled “A Novel Delivery System” chronicles the parts and processes governing use of the OncoSec Medical System (OMS) technology platform.

Dhillon’s published article also focuses on addressing the medical industry’s challenge to find safe and effective methods for delivering potentially useful agents to treat solid tumour cancers.

Currently, OncoSec is developing two platforms using its proprietary technology which include the OMS ElectroImmunotherapy program, now undergoing three ongoing Phase II programs for rare and deadly skin cancers as well as the company's late stage OMS ElectroChemotherapy program for the treatment of head and neck cancers.

The article can be read by clicking this link: http://www.onlinetmd.com/elecroporation-technology-cure-cancer.aspx

OncoSec uses its electroporation delivery system which applies cell membrane stimulation to deliver immunotherapy or chemotherapy to treat a range of cancerous tumour types.

The OMS electroporation system has proven to enhance cellular uptake, effectively treating cancerous cells while sparing surrounding healthy tissue cutting through the toxic side effects of current available treatment options like chemotherapy and radiation.

In 2011, the company managed to outline a clinical development plan for its local and potentially systemic ElectroImmunotherapy
program, which uses the OMS system to deliver a DNA-based immunotherapy, known as DNA IL-12.

DNA IL-12 IS designed to induce a local immune response against the treated cancerous tumour, while exploiting this response to initiate a global systemic response against untreated tumours in other areas of the body.

For the metastatic melanoma trial, a total of up to 25 patients with stage three or four cutaneous and in-transit metastatic
melanoma will be enrolled in the phase two, single-arm, open-label and multi-centre study.